Regorafenib: a novel drug for metastatic colorectal cancer treatment

Metastatic colorectal cancer is a serious medical and social problem. Development of new treatment approaches, drugs, especially targeted drugs, leads to the instantly increasing of survival in this disease. Regorafenib is recently approved for use in advanced metastatic colorectal cancer. This drug significantly improves treatment results with acceptable safety profile. In this review results of large controlled studies of regorafenib in colorectal cancer are discussed. Data on overall survival, progression-free survival, objective response rate and safety profile are consecutively evaluated.